Research programme: cancer therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: cancer therapeutics - Bristol-Myers Squibb

Alternative Names: BMS-536924; BMS-554417; BMS-673675; BMS-695735; BMS-698769; BMS-738533; BMS-743816; BMS-794833; BMT 062789

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Aminopyridines; Benzimidazoles; Heterocyclic compounds; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Epidermal growth factor receptor antagonists; Insulin-like growth factor-I receptor antagonists; Mitogen-activated protein kinase inhibitors; Proto oncogene protein c met inhibitors; Receptor protein-tyrosine kinase antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Dec 2016 Interim pharmacodynamics data from a preclinical studies in Lymphoma presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 03 Nov 2010 Preclinical trials in Cancer in China (PO)
  • 14 Dec 2008 Preclinical pharmacodynamics data presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top